Article Text

PDF
Extended report
Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway
  1. I González-Alvaro1,
  2. A M Ortiz1,
  3. C Domínguez-Jiménez1,
  4. A Aragón-Bodi1,
  5. B Díaz Sánchez1,
  6. F Sánchez-Madrid2
  1. 1
    Rheumatology, Hospital Universitario de la Princesa. Madrid, Spain
  2. 2
    Immunology Units, Hospital Universitario de la Princesa. Madrid, Spain
  1. Correspondence to Dr I Gonzalez-Alvaro, Rheumatology Unit, Hospital Universitario de la Princesa. Madrid, Spain; isidoro.ga{at}ser.es

Abstract

Objective: To study the effects of different disease-modifying antirheumatic drugs (DMARD) on different events mediated by IL-15-activated lymphocytes.

Methods: Peripheral blood lymphocytes (PBL) were isolated from healthy donors and activated with IL-15 after exposure to different DMARD: leflunomide, cyclosporin A, methotrexate, mycophenolic acid, FK-506, sulphasalazine and sodium aurothiomalate. The expression of different surface molecules on the PBL was then determined by flow cytometry. Cells were also co-cultured with the monocytic cell line THP-1 and the tumour necrosis factor (TNF) concentration in the supernatant was measured after 24 h using an immunoenzyme assay. The effect of the aforementioned drugs on IL-17 production by IL-15-activated PBL was also studied.

Results: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells. The downregulation of CD54 and CD69 in PBL was correlated with the inhibition of TNF production. Likewise, leflunomide, cyclosporin A and FK-506 all inhibited IL-17 production in IL-15-activated PBL. Interestingly, the effect of leflunomide was not reverted by the presence of uridine in the medium. In addition, leflunomide inhibited the phosphorylation of STAT6 in vitro.

Conclusion: Inhibition of the JAK/STAT pathway may represent an additional effect of leflunomide in chronic polyarthritis because it impairs certain events that control proinflammatory TNF and IL-17 cytokine production.

Statistics from Altmetric.com

Footnotes

  • Funding This work was funded by grants FIS 04/2009, 05/2041 and G03/152 from the Instituto de Salud Carlos III to IG-A.

  • Competing interests Declared. IG-A has received unrestricted grants from Abbott Laboratories and Bristol-Myers Squibb. CD-J was supported by grants from Sanofi-Aventis and Fundación Española de Reumatología. AA-B was supported by a DIB-SER grant from the Fundación Española de Reumatología.

  • Ethics approval Ethics approval was obtained.

  • ▸ Additional supplementary table 1 is published online only at http://ard.bmj.com/content/vol68/issue10

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.